Get the app
USHealthcare

SpyGlass Pharma, Inc. (SGP)

US · Healthcare · Biotechnology

$29.33+2.55%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-19.9M
EPS
$-0.59
EPS estimate
$-0.48

EPS came in at -0.59 against a street estimate of -0.48 — a miss of 22.9%.

Key statistics

Market cap
$920.5M
Forward P/E
0.0
P/B
3.97
Book value
$6.95
EPS (TTM)
$-1.68
52-week high
$32.44
52-week low
$17.06
50-day MA
$23.91
200-day MA
$23.70

Analyst view

with an average price target of $44.00.

Shareholding

Insiders
4.28%
Institutions
94.67%

Largest institutional holders

FundStake
RA Capital Management, LLC23.98%
NEA Management Company, LLC22.10%
Sands Capital Ventures, LLC7.47%
Samsara BioCapital, LLC6.31%
T. Rowe Price Associates, Inc.2.11%
Vestal Point Capital LP1.99%
JPMorgan Chase & Co1.73%
Deerfield Management Co1.64%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
SPYGLASS PHARMA, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $223.1 million in cash and equivalents as of June 30, 2026 (up from $
2026-08-06
Quarterly report · Q1 2026
SPYGLASS PHARMA, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $238.9 million in cash and cash equivalents as of March 31, 2026 (up
2026-05-14
Annual report FY2025
SPYGLASS PHARMA, INC. — FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: SpyGlass Pharma, Inc., traded as SGP on Nasdaq • Shares o
2026-03-26
Results announced · Q3 2026
SPYGLASS PHARMA Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and short-term investments: $234.2 million as of June 30, 2026 •
2026-08-06
Results announced · Q2 2026
SPYGLASS PHARMA Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and short-term investments: $251.0 million as of March 31, 2026
2026-05-14
Results announced · Q1 2026
SPYGLASS PHARMA - EARNINGS SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • IPO completed February 9, 2026: raised $172.5 million gross proceeds, lis
2026-03-26
Company announcement · Q1 2026
SPYGLASS PHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued press release on March 9, 2026 announcing positive 12-month clinical trial
2026-03-09

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for SpyGlass Pharma, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.